This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RTTR Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Ritter Pharmaceuticals Stock (NASDAQ:RTTR) 30 days 90 days 365 days Advanced Chart Get Ritter Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.37▼$3.8950-Day Range$0.45▼$4.0952-Week Range$0.15▼$1.27Volume45,396 shsAverage Volume14.23 million shsMarket Capitalization$157.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California. Read More Receive RTTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RTTR Stock News HeadlinesFBI raids NY home of ex-UN weapons inspector Scott RitterAugust 9, 2024 | nypost.comNDr. John D. RitterJanuary 23, 2024 | health.usnews.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.July 12 at 2:00 AM | Investors Alley (Ad)Kristen RitterSeptember 15, 2023 | health.usnews.comDr. Harold K. RitterJuly 8, 2023 | health.usnews.comDenver Business Journal welcomes new tech reporterJuly 1, 2023 | bizjournals.comJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkApril 10, 2023 | usatoday.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 29, 2023 | thestreet.comSee More Headlines RTTR Stock Analysis - Frequently Asked Questions How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. When did Ritter Pharmaceuticals' stock split? Ritter Pharmaceuticals shares reverse split on Friday, March 23rd 2018.The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Ritter Pharmaceuticals IPO? Ritter Pharmaceuticals (RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager. What other stocks do shareholders of Ritter Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), APA (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA) and Hudson Technologies (HDSN). Company Calendar Last Earnings5/01/2020Today7/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTTR CIK1460702 Webwww.ritterpharmaceuticals.com Phone310-203-1000FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.13 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.05% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book34.20Miscellaneous Outstanding Shares46,153,000Free FloatN/AMarket Cap$157.84 million OptionableNot Optionable Beta-0.43 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:RTTR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.